Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma

OBJECTIVE: Oral tyrosine kinase inhibitor has been shown to prolong progression-free survival (PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; however, the comparator arm has not included the current standard adenocarcinoma regimen (pemetrexed carboplatin induction f...

Descripción completa

Detalles Bibliográficos
Autores principales: Patil, Vijay Maruti, Noronha, Vanita, Joshi, Amit, Choughule, Anuradha Bharat, Bhattacharjee, Atanu, Kumar, Rajiv, Goud, Supriya, More, Sucheta, Ramaswamy, Anant, Karpe, Ashay, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ESMO Open 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519810/
https://www.ncbi.nlm.nih.gov/pubmed/28761735
http://dx.doi.org/10.1136/esmoopen-2017-000168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519810/
https://www.ncbi.nlm.nih.gov/pubmed/28761735
http://dx.doi.org/10.1136/esmoopen-2017-000168

Ejemplares similares